This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001 Study
ADSTILADRIN
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
ASTRO 2024
IBCN 2024
ESMO 2024
BCAN TT 2024
ASCO 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO 2017
ASCO 2017
Prostate Cancer
Bladder Cancer
Renal Cancer
Penile Cancer
Testicular Cancer
Adrenocortical Cancer
Press Releases
ASCO 2017 Prostate Cancer
Viewing 1-20 of 85 articles
ASCO 2017: Does Prostate Cancer Presentation and Biologic Characteristics Differ in Older Patients?
ASCO 2017: How Randomized Trials of STAMPEDE Have Influenced Treatment Decisions in the United Kingdom
ASCO 2017: Physical and Cognitive Effects of Systemic Therapy in Older Men with Prostate Cancer
ASCO 2017: Key Interdisciplinary and Integrated Treatment Planning Necessary to Effectively Treat Older Adults With Prostate Cancer
ASCO 2017: How Advances in Molecular Imaging Have Changed Our Understanding of State and Stage of the Disease
ASCO 2017: Neoadjuvant randomized trial of degarelix (Deg) ± cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP)
ASCO 2017: Targeting the AR: Biomarkers and Novel Therapeutic Approaches
ASCO 2017: Have Decisions by the National Institute for Health and Care Excellence Affected Outcomes of British Patients With Metastatic Castration-Resistant Prostate Cancer?
ASCO 2017: Intensification of Therapy for Locally Advanced and Oligometastatic Disease (Discussing Abstract 5018, 5019, 5020)
ASCO 2017: ARASENS phase 3 trial of ODM-201 in men with metastatic hormone-sensitive prostate cancer
ASCO 2017: PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration
ASCO 2017: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer
ASCO 2017: Androgen deprivation therapy in the treatment of prostate cancer and dementia risk: A systematic review and meta-analysis
ASCO 2017: Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1/2 clinical trial
ASCO 2017: Prostate cancer in 696 hypogonadal men with and without long-term testosterone therapy: Results from a controlled registry study
ASCO 2017: Phase 1b/2 keynote-365 trial: Pembrolizumab (pembro) combination therapy in metastatic castration-resistant prostate cancer
ASCO 2017: A phase II trial of abiraterone acetate (AA) without prednisone in castration resistant prostate cancer (CRPC)
ASCO 2017: Avelumab in metastatic castration-resistant prostate cancer (mCRPC)
ASCO 2017: Assessment of quality of life, cognitive function and depression in a randomized phase II study of abiraterone acetate (ABI) plus prednisone (P) vs enzalutamide (ENZA) for metastatic castrate-resistant prostate cancer (mCRPC)
ASCO 2017: Survival impact of initial local therapy selection for men under 60 with high risk prostate cancer
1
2
3
4
5
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free